Long-term HRQoL outcomes of dostarlimab + chemotherapy in patients with primary advanced or recurrent EC from the RUBY trial

Final analysis of NORA demonstrates the OS benefits of niraparib maintenance in Chinese PSROC patients regardless of gBRCAm status

Investigating the association between pretreatment thrombocytosis and ovarian cancer recurrence and survival

Mechanisms of ADC resistance and methods to overcome resistance

HRQoL improvements with pembrolizumab + CCRT and EBRT in high-risk LACC patients in ENGOT-CX11/GOG-3047/KEYNOTE A18

Validating PFS as a surrogate marker for OS in endometrial cancer treatment assessment: Results from an EORTC-YGCG systemic review

Improved prediction of PARPi responders in ovarian cancer patients using the Leuven PARPi benefit test

Integration of molecular classification in the 2023 FIGO staging forprognostic refinement in endometrial cancer